OXiGENE (OXGN) Announces Preclinical Data Presentation On Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity
11/18/2013 6:36:00 AM
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that researchers from Baylor University, with whom OXiGENE has a collaboration, are continuing to advance their discovery program focused on several small-molecule anticancer agents belonging to the benzosuberene class which are potent inhibitors of tubulin polymerization and are highly cytotoxic (in the picomolar to sub-picomolar range) against human cancer lines. Preclinical data presented today at the Southwest Regional Meeting (SWRM) of the American Chemical Society in Waco, TX emphasized the potential therapeutic utility of these benzosuberene compounds. The relative simplicity of their chemical structure coupled with their pronounced biological activity in vitro could enable them to be potent "payloads" in antibody-drug conjugates (ADCs) and to be used as cytotoxic agents in other targeted delivery strategies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by